Abstract
The alkaloid nicotine, a major addictive component of tobacco, exerts anti-inflammatory and immunemodulating activities on multiple cell types, such as T cells, B cells, dendritic cells, mononuclear phagocytes and polymorphonuclear leukocytes, in lung, spleen, liver, kidney and gastrointestinal tract. In addition, nicotine may blunt pro-inflammatory cytokine release, with prominent effects on T helper type 1 (Th1) and Th17 cytokines. The nonneuronal α7-nicotinic cholinergic receptors are a primary target for nicotine through the JAK2 and STAT3/NF-κB pathways, ultimately mediating the inhibition of pro-inflammatory gene transcription. The present paper reviews the growing evidence in favor of detrimental as well as beneficial effects of nicotine and other α7-nicotininc receptor agonists in pre-clinical models of organ-specific and systemic inflammatory and autoimmune diseases. These data may portend favorable implications for the targeted treatment of chronic and debilitating human disorders, such as diabetes, arthritis, asthma and inflammatory bowel disease, with α7-selective ligands.
Keywords: Nicotinic Receptors, immunity, inflammation, cytokines, cholinergic, anti-inflammatory, autoimmune encephalomyelitis, allergic asthma, arthritis, diabetes
Current Drug Targets
Title:The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Volume: 13 Issue: 5
Author(s): Perla Filippini, Alfredo Cesario, Massimo Fini, Franco Locatelli, Sergio Rutella
Affiliation:
Keywords: Nicotinic Receptors, immunity, inflammation, cytokines, cholinergic, anti-inflammatory, autoimmune encephalomyelitis, allergic asthma, arthritis, diabetes
Abstract: The alkaloid nicotine, a major addictive component of tobacco, exerts anti-inflammatory and immunemodulating activities on multiple cell types, such as T cells, B cells, dendritic cells, mononuclear phagocytes and polymorphonuclear leukocytes, in lung, spleen, liver, kidney and gastrointestinal tract. In addition, nicotine may blunt pro-inflammatory cytokine release, with prominent effects on T helper type 1 (Th1) and Th17 cytokines. The nonneuronal α7-nicotinic cholinergic receptors are a primary target for nicotine through the JAK2 and STAT3/NF-κB pathways, ultimately mediating the inhibition of pro-inflammatory gene transcription. The present paper reviews the growing evidence in favor of detrimental as well as beneficial effects of nicotine and other α7-nicotininc receptor agonists in pre-clinical models of organ-specific and systemic inflammatory and autoimmune diseases. These data may portend favorable implications for the targeted treatment of chronic and debilitating human disorders, such as diabetes, arthritis, asthma and inflammatory bowel disease, with α7-selective ligands.
Export Options
About this article
Cite this article as:
Perla Filippini, Alfredo Cesario, Massimo Fini, Franco Locatelli, Sergio Rutella , The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity , Current Drug Targets 2012; 13 (5) . https://dx.doi.org/10.2174/138945012800399008
DOI https://dx.doi.org/10.2174/138945012800399008 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Small Molecule CXCR4 Chemokine Receptor Antagonists: Developing Drug Candidates
Current Medicinal Chemistry CXCR2 Receptor Antagonists: A Medicinal Chemistry Perspective
Current Topics in Medicinal Chemistry New Insights on Neuronal Nicotinic Acetylcholine Receptors as Targets for Pain and Inflammation: A Focus on α7 nAChRs
Current Neuropharmacology Target-oriented Mechanisms of Novel Herbal Therapeutics in the Chemotherapy of Gastrointestinal Cancer and Inflammation
Current Pharmaceutical Design Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Safety of Inhaled Corticosteroids. Why the Variation in Systemic Adverse Effects?
Current Pediatric Reviews Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design L-Type Calcium Channels
Current Pharmaceutical Design Phenotyping and Endotyping Asthma Based on Biomarkers
Current Topics in Medicinal Chemistry Saint John on Patmos: Revelations of the Role of Antineutrophil Cytoplasmic Antibody (ANCA) in Vasculitis
Current Medicinal Chemistry Chitosan: A Propitious Biopolymer for Drug Delivery
Current Drug Delivery Pneumococcal Infections at Hajj: Current Knowledge Gaps
Infectious Disorders - Drug Targets Electronic Noses in Medical Diagnostics
Current Medicinal Chemistry Role of Interleukin-17F in Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Fluorinated Mechanism-Based Inhibitors: Common Themes and Recent Developments
Current Topics in Medicinal Chemistry Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Potential Role of Bioactive Lipids in Rheumatoid Arthritis
Current Pharmaceutical Design PET Radioligands for In Vivo Visualization of Neuroinflammation
Current Pharmaceutical Design Piperine: Medicinal, Analytical and Therapeutics perspective
Current Bioactive Compounds